AI in Medicine 2026: Where It Really Helps Today – and Where It Doesn’t

Hardly any topic is changing medicine as quickly as artificial intelligence (AI). But there is often a large gap between the headlines and everyday clinical practice. This overview explains where AI demonstrably helps in 2026, where the evidence is still thin and what patients should look out for.

What is meant by “AI in medicine”

The term covers very different technologies. The most widespread are pattern recognition systems that have been trained on large quantities of images or signals – such as X-ray and MRI scans, skin photos, tissue sections or ECG tracings. They mark abnormalities or calculate a probability. Since 2023, large language models (LLMs) that understand and generate text have been added: they summarise findings, pre-draft doctors’ letters or answer questions. A third group are prediction models that use laboratory and vital-sign data to estimate, for example, the risk of sepsis or of deterioration in hospital.

Where the benefit is best proven

The strongest evidence is in imaging. In the Swedish MASAI trial with more than 100,000 women, AI-supported reading of mammograms increased sensitivity from 73.8 to 80.5 per cent without reducing specificity; in an interim analysis, radiologists’ workload fell by 44 per cent. In Germany, the PRAIM study with more than 460,000 women in screening found 17.6 per cent more breast cancer cases when doctors used AI. More on this in our article AI in mammography screening.

The number of approved products is also growing: the US Food and Drug Administration (FDA) maintains a public list of AI-enabled medical devices with well over 1,000 entries. Around three quarters come from radiology. Other focus areas are cardiology, neurology and gastroenterology.

Where AI is arriving in everyday practice

• Documentation: so-called ambient scribes listen in on the consultation and produce a draft note. A randomised trial at UCLA with 238 doctors showed moderate time savings and somewhat less exhaustion – but also occasional relevant errors. More on this from 9 November in the article “AI takes notes”.
• Early detection: AI systems provide support in colonoscopy, ECG analysis and retinal examination of people with diabetes.
• Research: AI-designed drug candidates have reached the first clinical trials. More on this from 5 November in the article “AI in drug development”.

Where the limits lie

Good results on test datasets do not automatically mean benefit in practice. A study by the University of Oxford in Nature Medicine (2026) with around 1,300 participants showed that language models that solve medical exam questions very well did not help lay people make better decisions in realistic scenarios than a normal internet search. In addition, there are known risks such as biased training data, invented information (“hallucinations”) and a gradual loss of skill when professionals rely too heavily on the technology. We summarise these points from 6 November in the article “Risks of AI in medicine”.

Which rules apply

In the EU, software that supports diagnoses or treatment decisions is generally considered a medical device and must comply with the Medical Device Regulation (MDR). In addition, the European AI Act applies. Its obligations for high-risk AI in medical devices were postponed to August 2028 by the so-called Digital Omnibus. Details from 3 November in the article “The AI Act and medicine”.

What patients should know

• AI is generally a tool for professionals, not an independent doctor. Responsibility for diagnosis and treatment remains with humans.
• You are entitled to ask whether and how AI is being used in your examination.
• Chatbot answers to health questions can be helpful but do not replace an examination. If there are warning signs, the rule still applies: see a doctor, and in an emergency call 112.

Conclusion

In 2026, AI in medicine is no longer a promise for the future but is in well-evidenced use in certain areas – above all in imaging. In many other fields, large independent studies are still lacking. The key question is not whether AI is used, but how well it is tested, monitored and integrated into healthcare.

All articles in our AI focus series

• AI in mammography screening
• Asking ChatGPT and co. about your health (published on 1 November)
• AI in skin cancer detection (published on 2 November)
• The AI Act and medicine (published on 3 November)
• Health data as raw material for AI (published on 3 November)
• AI in cardiology (published on 4 November)
• AI in drug development (published on 5 November)
• Risks of AI in medicine (published on 6 November)
• AI in colonoscopy (published on 7 November)
• AI in pathology (published on 8 November)
• AI takes notes: documentation (published on 9 November)
• AI in ophthalmology (published on 10 November)
• AI in the operating theatre (published on 12 November)
• AI and mental health (published on 13 November)

And what comes next? Our series “The Future of Medicine” looks 5 to 100 years ahead.

Note: This article is for general information only and does not replace medical advice. As of: October 2026.

Sources

• ASCO Post: Randomized Trial Shows AI-Supported Mammography Improves Sensitivity (MASAI, The Lancet, February 2026)
• Pharmazeutische Zeitung: KI verbessert Brustkrebsscreening signifikant (PRAIM, Nature Medicine, January 2025)
• U.S. Food and Drug Administration: List of Artificial Intelligence-Enabled Medical Devices
• UCLA Health: AI scribes may reduce documentation time (NEJM AI, 2025)
• University of Oxford: New study warns of risks in AI chatbots giving medical advice (Nature Medicine, February 2026)
• Pure Global: EU AI Act – Digital-Omnibus verschiebt Hochrisiko-Fristen